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ABSTRACT
OBJECTIVES The aim of this study was to investigate the clinical outcomes of patients deferred from coronary
revascularization on the basis of instantaneous wave-free ratio (iFR) or fractional ﬂow reserve (FFR) measurements in
stable angina pectoris (SAP) and acute coronary syndromes (ACS).
BACKGROUND Assessment of coronary stenosis severity with pressure guidewires is recommended to determine the
need for myocardial revascularization.
METHODS The safety of deferral of coronary revascularization in the pooled per-protocol population (n ¼ 4,486)
of the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation) and
iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina
Pectoris or Acute Coronary Syndrome) randomized clinical trials was investigated. Patients were stratiﬁed according to
revascularization decision making on the basis of iFR or FFR and to clinical presentation (SAP or ACS). The primary
endpoint was major adverse cardiac events (MACE), deﬁned as the composite of all-cause death, nonfatal myocardial
infarction, or unplanned revascularization at 1 year.
RESULTS Coronary revascularization was deferred in 2,130 patients. Deferral was performed in 1,117 patients (50%) in
the iFR group and 1,013 patients (45%) in the FFR group (p < 0.01). At 1 year, the MACE rate in the deferred population
was similar between the iFR and FFR groups (4.12% vs. 4.05%; fully adjusted hazard ratio: 1.13; 95% conﬁdence interval:
0.72 to 1.79; p ¼ 0.60). A clinical presentation with ACS was associated with a higher MACE rate compared with SAP in
deferred patients (5.91% vs. 3.64% in ACS and SAP, respectively; fully adjusted hazard ratio: 0.61 in favor of SAP; 95%
conﬁdence interval: 0.38 to 0.99; p ¼ 0.04).
CONCLUSIONS Overall, deferral of revascularization is equally safe with both iFR and FFR, with a low MACE rate
of about 4%. Lesions were more frequently deferred when iFR was used to assess physiological signiﬁcance.
In deferred patients presenting with ACS, the event rate was signiﬁcantly increased compared with SAP at 1 year.
(J Am Coll Cardiol Intv 2018;11:1437–49) © 2018 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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primary hypothesis, that iFR was noninferior to FFR

medical therapy in the intervening 17 years (3).

for major adverse cardiac events (MACE) at 1 year in
patients undergoing physiologically guided revascu-

SEE PAGE 1450

Recently,

2

large

randomized

larization decision making.
clinical

trials,

DEFINE-FLAIR (Functional Lesion Assessment of In-

STUDY

termediate Stenosis to Guide Revascularisation) and

analyzed the merged populations of the DEFINE-

POPULATION. Our

iFR-SWEDEHEART (Instantaneous Wave-Free Ratio

FLAIR and iFR-SWEDEHEART randomized clinical

Versus Fractional Flow Reserve in Patients With

trials. These patients had an indication for physio-

Stable Angina Pectoris or Acute Coronary Syndrome),

logical assessment of at least 1 coronary lesion in

compared the clinical outcomes of 4,529 patients with

which the functional severity was questionable (40%

coronary stenoses undergoing either FFR-based or

to 80% stenosis by visual assessment). This study

instantaneous wave-free ratio (iFR)–based revascu-

included patients with SAP and ACS (unstable angina

larization, the latter a novel adenosine-free index of

pectoris,

non–ST-segment

study

combined

elevation

and

myocardial

stenosis severity (6,7). The combined dataset of both

infarction [MI], and ST-segment elevation MI). In

studies provides a unique opportunity to revisit the

patients with SAP, any lesion could be assessed. In

safety of physiology-guided deferral of revasculari-

patients with ACS, physiological interrogation was

zation in contemporary clinical practice, with the

performed only in the nonculprit artery once the

added value of depicting the predominant clinical

culprit vessel was revascularized. In the case of

use of FFR, which is interrogation of stenoses with

ST-segment elevation MI, nonculprit vessels were

intermediate angiographic severity (8–10).

evaluated >48 h after primary PCI. Inclusion and

In this study, we investigated the 1-year clinical

exclusion criteria are listed in the Online Appendix.

outcomes of patients who were included in the per-

In both trials, all participants provided written

protocol populations of the DEFINE-FLAIR and iFR-

informed consent before enrollment.

SWEDEHEART randomized trials. As both trials

PROCEDURE. Physiological measurements were per-

included patients with stable angina pectoris (SAP)

formed in the usual manner using the same coronary

and acute coronary syndromes (ACS), the safety of

pressure guidewire (Verrata, Philips Volcano, San

revascularization deferral in both clinical scenarios

Diego,

could be compared. This may shed light on conﬂicting

coronary nitrates were administered to control vaso-

reports regarding the comparable safety of revascu-

motor tone. Pre-speciﬁed treatment thresholds were

larization deferral in patients in stable condition and

0.89 for iFR and 0.80 for FFR. Stenoses were revas-

in those presenting with ACS (11–15).

cularized with either PCI or coronary artery bypass

METHODS

grafting. When iFR or FFR exceeded these pre-

California).

Before

measurement,

intra-

speciﬁed thresholds, treatment was deferred. PresSTUDY

DESIGN. The

DEFINE-FLAIR

and

iFR-

sure drift was assessed using the pressure ratio at the

SWEDEHEART trial designs have been previously

catheter tip after each physiological measurement.
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F I G U R E 1 Flowchart of the Study

DEFINE-FLAIR trial
2492 patients included

43 patients were
excluded
-protocol violations: 29
-technical issues: 8
-other: 6

iFR-SWEDEHEART trial
2037 patients included

4486 patients were analyzed
2350 patients* were
treated according to
pressure wire

In 2130 patients* PCI was
deferred based on pressure
wire(iFR ≥0.90 or FFR >0.80)

440** patients
presented with ACS

222 patients were
assessed with iFR

218 patients were
assessed with FFR

1675** patients
presented with SAP

885 patients were
assessed with iFR

790 patients were
assessed with FFR

* deferral/treated status unknown for 6 patients
** disease type unknown for 15 patients among deferred patients

A combined total of 4,529 participants were enrolled in the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide
Revascularisation) and iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina
Pectoris or Acute Coronary Syndrome) randomized clinical trials. ACS ¼ acute coronary syndrome(s); FFR ¼ fractional ﬂow reserve; iFR ¼
instantaneous wave-free ratio; PCI ¼ percutaneous coronary intervention; SAP ¼ stable angina pectoris.

If the pressure ratio exceeded 0.02, physiological

outcomes were adjudicated by the clinical event

measurements were repeated. For patients assigned

adjudication committee in DEFINE-FLAIR and by an

to FFR, hyperemia was obtained with intravenous or

independent experienced observer who was unaware

intracoronary

of the group assignments in iFR-SWEDEHEART.

hyperemic

agents

as

previously

described (6,7). When multivessel revascularization
was required, investigators could stage procedures
within 60 days of the index measurement. Revascularization was performed according to standard clinical practice, with pharmacological therapy left to the
discretion of the treating physician.

STATISTICAL ANALYSIS. The objective of this study

was to compare event rates between physiological
techniques (iFR vs. FFR) in patients for whom
revascularization was deferred on the grounds of
physiological measurements. Additionally, we investigated whether clinical presentation (SAP vs. ACS)

ENDPOINTS. The primary safety endpoint of the

inﬂuenced event rates and subsequently if this was

study was the composite of MACE, deﬁned as

modiﬁed by which physiological technique was used

all-cause death, nonfatal MI, or unplanned revascu-

to guide decision making.

larization within 12 months of the index procedure.

For MACE and its components, a time-to-event

Secondary endpoints were the individual compo-

analysis was performed in the per-protocol popula-

nents of MACE. In both DEFINE-FLAIR and iFR-

tion by Cox survival modeling. Participants who

SWEDEHEART, death and MI were adjudicated with

withdrew from the study before reaching 1 year of

anonymized source documentation by independent

follow-up and who were event free at their last visit

clinical event adjudication committees, whose mem-

were censored at their time of last visit. Testing of

bers were unaware of the group assignments. A

the validity of the proportional hazards assumption

consensus decision was made on the basis of the

was done using Schoenfeld residuals. There were no

pre-speciﬁed

signs

endpoint

deﬁnitions.

Unplanned

revascularization events and secondary angiographic

of

assumption.

violations

of

proportional

hazards
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T A B L E 1 Baseline Characteristics of the Deferred Population

iFR
(n ¼ 1,117)

FFR
(n ¼ 1,013)

Age (yrs)

66.1  10.7

66.6  9.9

0.55

Male

72.0 (804)

68.0 (689)

0.05

Body mass index (kg/m2)

27.5  4.7

27.5  5.0

0.51

Diabetes mellitus

21.8 (243)

24.8 (251)

0.19

p Value

Canadian Cardiovascular Society class for grading of
angina pectoris, diabetes, hypertension, hyperlipidemia, smoking status, previous MI, and previous PCI.
Fully adjusted results are presented in the text and
both unadjusted and fully adjusted in the tables.

RESULTS

Hypertension

71.1 (794)

71.7 (726)

0.32

STUDY POPULATION. A combined total of 4,529

Hyperlipidemia

68.5 (765)

66.3 (672)

0.52

participants were enrolled in both trials; 2,261 were

Current smoker

19.0 (212)

17.8 (180)

assigned to the iFR group and 2,268 to the FFR group

Previous MI

30.1 (336)

30.4 (308)

0.09

(Figure 1). Data for 43 patients were excluded from the

Previous PCI

42.6 (476)

43.4 (440)

0.57

analyses because of unacceptable side effects associ-

<0.01

ated with adenosine, technical issues, incorrect group

CCS angina class
I
II
III
IV
Clinical presentation
Acute coronary syndrome
Stable angina pectoris
No information

26.8 (299)
32.8 (366)
4.8 (54)
1.8 (20)

22.5 (228)
27.9 (283)
7.8 (79)
2.3 (23)

assignment, or other reasons; data for the remaining
4,486 patients were included in the analyses.
0.36

19.9 (222)
79.2 (885)
0.9 (10)

21.5 (218)
78.0 (790)
0.5 (5)

Values are mean  SD or % (n).
CCS ¼ Canadian Cardiovascular Society; FFR ¼ fractional ﬂow reserve; iFR ¼
instantaneous wave-free ratio; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention.

BASELINE CHARACTERISTICS. In the overall study

population, the mean age was 66.3 years, 26.6% of
patients had diabetes mellitus, 72.2% had SAP, and
31.0% had history of MI. No differences were found in
baseline characteristics between the iFR and FFR
groups (Online Table 1).
Coronary revascularization was deferred in 2,130
patients. Deferral was performed in 1,117 patients
(50%) in the iFR group and 1,013 patients (45%) in the

Results are reported using hazard ratios (HRs), 95%

FFR group (p < 0.01). The baseline characteristics of

2-sided conﬁdence intervals (CIs), and cumulative

patients deferred by iFR and FFR methods are dis-

hazard curves. Analyses were performed in an unad-

played in Table 1. The iFR group included a higher

justed manner as well as adjusted for the following

proportion of male patients than the FFR group

baseline characteristics that were chosen a priori for

(72.0% vs. 68.0%; p ¼ 0.05). Canadian Cardiovascular

their known associations with cardiovascular events:

Society grading of angina pectoris was signiﬁcantly

age, sex, body mass index, clinical presentation,

higher in the iFR group (26.8% in class I and 32.8% in

F I G U R E 2 Distribution of Physiological Values

Histograms of FFR (left) and iFR (right) values in the deferred pooled patient population of the DEFINE-FLAIR and iFR-SWEDEHEART randomized clinical trials.
Abbreviations as in Figure 1.
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T A B L E 2 Procedural Characteristics of the Deferred Population

iFR
(n ¼ 1,117)

Site of access
Radial

FFR
(n ¼ 1,013)

p Value

0.60

Procedure time (min)
Median
Interquartile range

Mean iFR/FFR value

min; interquartile range: 24 to 48 min) (p ¼ 0.02).
PRIMARY ENDPOINT AND COMPONENTS. There was

no censoring before 12 months in iFR-SWEDEHEART;

76.2 (851)

75.2 (762)

30
20–45

34
24–48

tarily withdrew from the study before 12 months and

1,478

1,317

overall study population, at 1 year, the primary

0.95  0.03

0.89  0.05

0.02

Total number of vessels
evaluated

range: 20 to 45 min) than in the FFR group (median 34

150 patients (6.1% of 2,467) in DEFINE-FLAIR volunwere censored at the time of their last visit. In the
endpoint had occurred in 145 of 2,240 patients
(6.47%) in the iFR group and in 144 of 2,246 (6.41%)
in the FFR group (unadjusted HR: 1.03; 95% CI: 0.81

Values are % (n) or mean  SD, unless otherwise indicated.

to 1.31; p ¼ 0.81) (Online Figure 1). No signiﬁcant

Abbreviations as in Table 1.

differences were noted in terms of the components of
the primary endpoint in both study arms (Online
class II) than in the FFR group (22.5% in class I and

Table 2). The number of deaths from any cause at 12

27.9% in class II) (p < 0.01 for the difference between

months did not differ signiﬁcantly between the iFR

groups). The remaining baseline characteristics were

group (36 deaths, including 15 from cardiovascular

otherwise well balanced between the iFR- and FFR-

causes) and the FFR group (25 deaths, including 10

deferred groups.

from cardiovascular causes) (p ¼ 0.14). The rates of

When the deferred population was stratiﬁed according to clinical presentation, overall less lesions

nonfatal MI and unplanned revascularization did not
differ signiﬁcantly between the 2 groups.

were deferred in ACS compared with clinical presen-

When stratiﬁed according to clinical presentation,

tation with SAP (36% vs. 50%; p < 0.001). In SAP, more

the overall MACE rate in patients with ACS (7.7%) was

lesions were deferred with iFR than FFR (55% vs.

higher than in patients with SAP (6.0%) (fully

48%; p < 0.001). In ACS, deferral rates were similar for

adjusted HR: 0.72 in favor of SAP; 95% CI: 0.55 to

both iFR and FFR guidance (36% vs. 36%; p ¼ 0.91).

0.93; p ¼ 0.01) (Online Table 3). In the deferred pop-

PROCEDURAL CHARACTERISTICS. In the deferred

population, mean iFR was 0.95  0.03 and mean FFR
was 0.89  0.05. The distribution of iFR and FFR
values is displayed in Figure 2. The procedural characteristics for the deferred populations are displayed
in Table 2. The numbers of physiological evaluations
per patient were 1.32  0.67 for iFR and 1.30  0.62 for
FFR (p ¼ 0.67). Total procedure time was signiﬁcantly
shorter in the iFR group (median 30 min; interquartile

ulation, this difference was driven mainly by a higher
1-year MACE rate among the deferred patients with
ACS (26 of 440 [5.9%]) compared with deferred patients with SAP (61 of 1,675 [3.6%]) (fully adjusted HR:
0.61 in favor of SAP; 95% CI: 0.38 to 0.99; p ¼ 0.04)
(Table 3).
In the deferred population, at 1 year, the primary
endpoint occurred in 46 of 1,117 patients (4.12%) in
the iFR group and in 41 of 1,013 patients (4.05%) in
the FFR group (fully adjusted HR: 1.13; 95% CI: 0.72 to
1.79; p ¼ 0.60) (Figure 3). The HRs for the individual

T A B L E 3 Time-to-Event Analysis for Major Adverse Cardiac Events and Their

components of MACE for iFR- versus FFR-guided

Components According to Clinical Presentation (Stable Angina Pectoris Versus

deferral are displayed in Table 4. Unplanned revas-

Acute Coronary Syndromes) in Deferred Patients

cularization was the biggest contributor numerically
SAP vs. ACS

SAP
ACS
(n ¼ 1,675) (n ¼ 440)

Unadjusted HR
(95% CI)

Fully Adjusted
HR (95% CI)

to the total MACE rate for both iFR- and FFR-deferred
p Value

MACE

3.64 (61)

5.91 (26) 0.62 (0.39–0.99) 0.61 (0.38–0.99)

0.04

All-cause death

0.66 (11)

1.36 (6)

0.44 (0.16–1.23)

0.12

Cardiovascular death

0.50 (0.19–1.36)

0.18 (3)

0.45 (2)

0.41 (0.07–2.45)

0.21 (0.02–1.71)

0.14

Noncardiovascular death 0.48 (8)

0.91 (4)

0.55 (0.16–1.82)

0.46 (0.13–1.59)

0.22

Myocardial infarction

2.50 (11)

0.34 (0.16–0.76) 0.36 (0.16–0.79)

0.01

2.87 (48) 3.64 (16) 0.81 (0.46–1.43) 0.83 (0.46–1.49)

0.53

Unplanned
revascularization

0.90 (15)

groups (2.78% and 3.26%, respectively; p ¼ 0.63).
There were no signiﬁcant differences in the components

of

MACE

between

the

2

physiological

techniques.
Within the deferred group, the MACE rate was
more inﬂuenced by clinical presentation in patients
evaluated with FFR (unadjusted HR: 0.52 in favor of
SAP; 95% CI: 0.27 to 1.00; p < 0.05) than in those
evaluated with iFR (unadjusted HR: 0.74 in favor of

Values are % (n), unless otherwise indicated.
ACS ¼ acute coronary syndrome(s); CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiac
event(s); SAP ¼ stable angina pectoris.

SAP; 95% CI: 0.38 to 1.43; p ¼ 0.37) (Table 5), with a
statistically nonsigniﬁcant interaction (Figure 4). The
effect of clinical presentation on MI rate was more
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marked in the FFR group (unadjusted HR: 0.28 in
favor of SAP; 95% CI: 0.09 to 0.88) than in the iFR

F I G U R E 3 Cumulative Risk for Primary Endpoint (Major Adverse Cardiac Events) by

Physiological Technique in the Deferred Population

group (unadjusted HR: 0.42 in favor of SAP; 95% CI:
0.14 to 1.27), but the interaction was not statistically
signiﬁcant.

DISCUSSION
The present study demonstrates that the revascularization of intermediate stenoses in patients with SAP
can be safely deferred on the grounds of iFR or FFR
measurements. In patients with ACS, deferral was
associated with more cardiovascular events at followup, compared to patients with SAP.
DEFERRAL OF REVASCULARIZATION: A KEY ASPECT
OF

PHYSIOLOGY-GUIDED

REVASCULARIZATION.

Physiology-guided revascularization is the current
main application of coronary physiology in the
catheterization laboratory. It aims to improve patient outcomes by restricting revascularization to

Shown is the cumulative risk for the composite of death from any cause, nonfatal

stenoses that cause myocardial ischemia (2,16).

myocardial infarction, or unplanned revascularization at 1 year. MACE ¼ major adverse

Because coronary angiography is an inadequate

cardiac event(s); other abbreviations as in Figure 1.

diagnostic tool for estimating functional stenosis
severity, particularly in intermediate stenoses (17),
the predominant role of intracoronary physiology is

with MI, and 10.4% required repeat revascularization

to serve as a gatekeeper to revascularization in in-

(19). In the FAME II trial, 166 registry patients (those

termediate stenoses (18).

with FFR >0.80) were followed up. At 2 years, 9% of

The pivotal DEFER trial, in which 92 of the 325

patients had reached the primary endpoint. Looking

patients included were randomized to PCI deferral,

at the components of the primary endpoint, the

consolidated the

concept that FFR-based post-

mortality rate was 1.2%, the MI rate 5.4%, and the

ponement of revascularization is safe (3). However,

urgent revascularization rate 5.4% (16). Ahn et al.

translation of the trial to contemporary clinical

(20) enrolled 5,846 patients in a prospective multi-

practice is hampered not only by the fact that the

center study from 2009 to 2015 who had revascu-

0.75 FFR cutoff in the study has been abandoned

larization guided by FFR (6,468 deferred lesions,

from treatment guidelines but also primarily by the

2,165 treated lesions). In this study, the risk for

evolution of treatment over the past 20 years:

cardiac events in deferred lesions, at a median

balloon angioplasty as a stand-alone therapy has
virtually been abandoned, drug-eluting stents have
been developed, and more potent antiplatelet agents
and other medical therapies have become available.

T A B L E 4 Outcomes in the Overall Deferred Population According to

Instantaneous Wave-Free Ratio or Fractional Flow Reserve

Furthermore, subsequent randomized studies such

iFR vs. FFR

as the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) trial, although

iFR
FFR
(n ¼ 1,117) (n ¼ 1,013)

Unadjusted
HR (95% CI)

Fully Adjusted
HR (95% CI)

4.12 (46) 4.05 (41)

1.05 (0.69–1.60)

1.13 (0.72–1.79)

0.60

0.59 (6)

1.68 (0.62–4.55)

2.21 (0.68–7.13)

0.19

p Value

performed in the stent era, were conducted in study

MACE

populations that do not align with guidelines for the

All-cause death

0.98 (11)

recommended use of coronary physiology to guide

Cardiovascular death

0.36 (4)

0.10 (1)

3.66 (0.41–32.76) 2.53 (0.23–28.32)

0.45

decision making. Mean FFR in FAME was 0.71, while

Noncardiovascular death 0.63 (7)

0.49 (5)

1.29 (0.41–4.05) 2.04 (0.51–8.13)

0.31

FFR

in

DEFINE-FLAIR

and

iFR-SWEDEHEART

studies was close to the 0.80 cutoff, which is in
agreement with all other contemporary registries

Myocardial infarction

1.16 (13)

1.28 (13) 0.99 (0.45–2.18)

1.00 (0.44–2.28)

1.00

Unplanned
revascularization

2.78 (31)

3.26 (33) 0.86 (0.53–1.40) 0.88 (0.52–1.49)

0.63

and trials (8–10).
In the FAME trial, 513 lesions were deferred in 509
patients. At 2 years, 1.8% of patients had presented

Values are % (n), unless otherwise indicated.
Abbreviations as in Tables 1 and 3.
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T A B L E 5 Outcomes in the Overall Deferred Population According to Clinical Presentation

based largely on registry data, not randomized clin-

(Stable Angina Pectoris Versus Acute Coronary Syndrome) and Effect Modiﬁcation by

ical trials comparing outcomes in patients with ACS

Physiological Technique

compared with those with SAP.
SAP
(n ¼ 1,675)

ACS
(n ¼ 440)

SAP vs. ACS
Unadjusted HR
(95% CI)

MACE
FFR
iFR

3.64 (61)
3.42 (27)
3.84 (34)

5.91 (26)
6.42 (14)
5.41 (12)

0.62 (0.39–0.99)
0.52 (0.27–1.00)
0.74 (0.38–1.42)

0.04

All-cause death
FFR
iFR

0.66 (11)
0.51 (4)
0.79 (7)

1.36 (6)
0.92 (2)
1.80 (4)

0.50 (0.19–1.36)
0.57 (0.10–3.13)
0.46 (0.13–1.57)

0.17

Cardiovascular death
FFR
iFR

0.18 (3)
0.00 (0)
0.34 (3)

0.45 (2)
0.46 (1)
0.45 (1)

0.41 (0.07–2.45)

0.33

0.78 (0.08–7.52)

Noncardiovascular
death
FFR
iFR

0.48 (8)

0.91 (4)

0.55 (0.16–1.82)

0.51 (4)
0.45 (4)

0.46 (1)
1.35 (3)

1.14 (0.13–10.24)
0.35 (0.08–1.56)

Myocardial infarction
FFR
iFR

0.90 (15)
0.89 (7)
0.90 (8)

2.50 (11)
2.75 (6)
2.25 (5)

0.34 (0.16–0.76)
0.28 (0.09–0.88)
0.42 (0.14–1.27)

0.01

Urgent revascularization
FFR
iFR

2.87 (48)
2.78 (22)
2.94 (26)

3.64 (16)
5.05 (11)
2.25 (5)

0.81 (0.46–1.43)
0.56 (0.27–1.16)
1.36 (0.52–3.53)

0.47

p
Value

Interaction
p Value

DEFERRAL OF REVASCULARIZATION WITH EITHER
FFR OR iFR. The recently published DEFINE-FLAIR

and iFR-SWEDEHEART trials
0.46

demonstrated

that

iFR is noninferior to FFR in terms of clinical outcomes associated with ischemia-driven revascularization

0.83

(6,7).

These

trials

provide

the

ﬁrst

opportunity to assess the validity of PCI deferral
with a pressure-derived index of stenosis severity
other than FFR. Of note, both studies consistently
demonstrated that fewer stenoses were deemed
hemodynamically signiﬁcant when iFR was used. As

0.32
0.38

this implies a higher rate of PCI deferral when iFR
is used as a diagnostic tool, comparing the outcomes of patients who had iFR or FFR determined

0.64

PCI deferral is an objective of the utmost clinical
importance.

0.15

Overall, iFR and FFR are equally safe in deferring
revascularization, with event rates in our study of
4.12% and 4.05%, respectively (fully adjusted HR:

Values are % (n), unless otherwise indicated.
Abbreviations as in Tables 1 and 3.

1.13; 95% CI: 0.72 to 1.79; p ¼ 0.60). These event rates,
at 1-year follow-up, are virtually one-half of those
reported for deferred patients in the DEFER trial (8%)

follow-up of 1.9 years, was linearly associated with
FFR values. When FFR was >0.70, the higher the

(3), reﬂecting the evolution of interventional and
medical therapy.

FFR value, the lower the incidence of cardiac events.

DEFERRAL OF REVASCULARIZATION IN PATIENTS

However, contemporary evidence supporting the

WITH ACS. The evidence supporting the safety of

safety of FFR-based revascularization deferral is

deferral of PCI in patients with ACS on the basis of

F I G U R E 4 Cumulative Risk for Primary Endpoint (Major Adverse Cardiac Events) by Clinical Presentation in Patients Assessed With Fractional Flow Reserve and

Instantaneous Wave-Free Ratio in the Deferred Population

Shown is the cumulative risk for the composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization at 1 year, stratiﬁed according to
clinical presentation with either stable angina pectoris (SAP) or acute coronary syndrome (ACS). Data for fractional ﬂow reserve (FFR) (left) and instantaneous wavefree ratio (iFR) (right) are displayed.
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The

presentation with ACS was identiﬁed in a multi-

conclusions of the DEFER trial, based on patients

variate Cox model as the most powerful indepen-

with SAP, are therefore not applicable in contem-

dent

porary clinical practice, in which ACS is a very

intervention deferral (adjusted HR: 2.74; 95% CI:

common indication for PCI. A substudy of the FAME

1.13 to 6.64; p ¼ 0.026). In contrast, our ﬁndings are

trial documented a higher prevalence of 2-year

not concordant with those obtained in the pooled

MACE

had

population of 2 separate registries, including 1,983

physiology-guided PCI performed (21.3%), compared

patients, of whom 533 presented with ACS (22). At

with 359 patients with SAP included in the trial

1-year follow-up, FFR-based deferral was associated

(16.4%); importantly, that study did not report

with similar MACE rates in patients presenting with

separately the outcomes of deferred patients ac-

ACS and SAP (8.0% vs. 8.5% with ACS and SAP,

cording to clinical presentation (21). Recent ran-

respectively; p ¼ 0.83). Of note, MACE rates in that

domized trials addressing the safety of FFR-guided

registry were markedly higher than in our study,

revascularization of nonculprit stenoses in patients

particularly in patients with SAP (8.5% vs. 3.6% in

with ACS and multivessel disease (11,12) have

our study).

focused only on the ACS subset, not comparing the

INFLUENCE OF CLINICAL PRESENTATION ON THE

long-term outcomes with patients with SAP when

SAFETY

revascularization is deferred on the basis of FFR

STENOSIS SEVERITY. Whether the observed higher

(2,16). Furthermore, these trials included small

event rates among patients with ACS are due to their

numbers

non–ST-

inherent higher risk or to inadequate stenosis

segment elevation MI, therefore contributing to the

assessment with pressure guidewires is unclear. From

paucity of data on this important topic. A further

contemporary trial data (23) patients presenting with

limitation is that much evidence in this population

ACS have increased cardiovascular risk after stabili-

comes from observational data rather than ran-

zation, with respective 1-year rates of MI and death of

domized clinical trials.

5.8% and 2.4%.

pressure-derived

in

150

of

measurements

patients

patients

is

with

presenting

limited.

ACS

who

with

predictor

OF

of

MACE

after

PRESSURE-DERIVED

FFR-based

INDEXES

OF

The present analysis conﬁrms that among pa-

In our analysis, we found that MACE in deferred

tients who had revascularization deferred, those

patients with ACS were driven largely by coronary

presenting with ACS had a higher 1-year MACE rate

revascularization, although both MI and death also

than those presenting with SAP (5.91% vs. 3.64%;

contributed. This might provide indirect support for

fully adjusted HR: 0.61; 95% CI: 0.38 to 0.99;

the concept that in patients with ACS, pressure-

p ¼ 0.04) (Table 3). These ﬁndings are in agreement

based indexes do not consistently identify the ste-

with recently reported studies (13,14). Hakeem et al.

noses for which revascularization can be safely de-

(14) found that FFR-based deferral of PCI in patients

ferred. Furthermore, other studies have reported

with ACS was associated with a more than 2-fold

repeat revascularization as an important contributor

increase in the combined endpoint of MI or target

to MACE in patients presenting with ACS who had

vessel

follow-up

revascularization deferred on the grounds of FFR

compared with patients with SAP (23% vs. 11%,

interrogation (13–15). As we did not assess the

respectively, p < 0.0001). Masrani Mehta et al. (13)

characteristics

reported similar ﬁndings in a retrospective analysis

nonculprit

of a series of 674 patients, of whom 334 presented

increased risk attributable to vulnerable lesions in

with ACS. At a mean follow-up of 4.5 years, patients

these patients cannot be ruled out. Such risk might

revascularization

at

3.4-year

of

vessels

the
in

atheromatous
patients

with

plaques
ACS,

in
an

with ACS had a signiﬁcantly higher MACE rate

be ampliﬁed by the presence of systemic inﬂam-

than those with SAP (32% vs. 23%, respectively,

mation, which has been documented in patients

p ¼ 0.02). Lee et al. (15) reported, as part of a

with ACS (24).

prospective, international registry on FFR use, the

The excess of risk for physiology-based stenosis

long-term outcomes (mean 2.1 years) after FFR-

deferral in patients with ACS may reﬂect the sub-

based deferral of revascularization in 1,596 pa-

stantially different physiological conditions found in

tients, of whom 301 presented with ACS. Deferral of

these patients from those in patients with SAP.

revascularization in nonculprit stenoses in patients

Although FFR has been extensively validated as a

with ACS (n ¼ 409) was associated with a more than

clinical tool in patients with SAP, its value in patients

2-fold increase in MACE compared with deferral of

with ACS is less well described. Microcirculatory

stenoses in patients with SAP (adjusted HR: 2.97;

vasodilation during hyperemia can be transiently

95%

CI:

1.33

to

7.17;

p

¼

0.026).

Clinical

blunted in the acute phase of ACS, affecting also
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myocardial territories remote to those subtended by
nonculprit stenoses (25). We explored whether iFR or

ADDRESS FOR CORRESPONDENCE: Dr. Justin E.

FFR resulted in better long-term outcomes of stenosis

Davies, Hammersmith Hospital, Imperial College NHS

deferral in patients with ACS. However, the negative

Trust, Du Cane Road, London, W12 0HS, United

outcome associated with ACS presentation on 1-year

Kingdom. E-mail: justindavies@heart123.com.

outcomes after revascularization deferral was not
signiﬁcantly inﬂuenced by the use of either iFR or
FFR, even when the individual components of MACE

PERSPECTIVES

were analyzed separately. Numerically, we observed
higher rates of MACE in the ACS compared with SAP
cohort among patients deferred with FFR. This difference in rates was less pronounced in patients deferred with iFR.
STUDY LIMITATIONS. This was a nonrandomized

subset of 2 prospective randomized trials, but the
results have been fully adjusted for baseline clinical
characteristics. Both iFR and FFR are continuous
variables, which were reported and acted in a
dichotomous manner (i.e., treat or do not treat if
below or above a threshold), and therefore relevant
clinical information is omitted from the decision-

WHAT IS KNOWN? DEFINE-FLAIR and iFRSWEDEHEART are the largest coronary physiology
clinical outcome trials ever conducted. Within the
trials, overall MACE rates at 1 year were similar for
both iFR- and FFR-guided populations. However, the
clinical outcomes of patients who had coronary
revascularization deferred on the basis of iFR or FFR
measurements, and the inﬂuence of clinical presentation (SAP and ACS) on outcomes, are unknown.
WHAT IS NEW? Despite a higher rate of deferral
with iFR, clinical outcomes for both iFR- and FFR-

making process. In DEFINE-FLAIR, both the patients

deferred populations were similar at 1 year. This in-

and the treating physicians remained blinded to

dicates that deferral of coronary revascularization by

group assignments, whereas in iFR-SWEDEHEART,

either iFR or FFR methods is equally safe. However,

both were aware of the group assignment.

deferral of patients with ACS was associated with a
signiﬁcant increase in event rates at 1 year compared

CONCLUSIONS

with patients with SAP.

Overall, deferral of revascularization is equally safe
with both iFR and FFR, with a low MACE rate of
approximately 4%. Lesions were more frequently
deferred when iFR was used to assess physiological
stenosis signiﬁcance. Deferral of patients with ACS is
associated with a signiﬁcant increase in event rates at

WHAT IS NEXT? Reporting of longer term clinical
outcomes from the DEFINE-FLAIR and iFRSWEDEHEART trials are awaited. Furthermore, analyses of key substudy populations of clinical interest
are ongoing.

1 year compared with patients with SAP.
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